Výsledky vyhledávání

Akademický článek

Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome

Autor: Stéphane Auvin, Blandine Dozières‐Puyravel, Andreja Avbersek, David Sciberras, Jo Collier, Karine Leclercq, Pavel Mares, Rafal M. Kaminski, Pierandrea Muglia

Publikováno v: Annals of Clinical and Translational Neurology, Vol 7, Iss 3, Pp 343-352 (2020)

Abstract Objective Infantile spasm syndrome (ISS) is an epileptic encephalopathy without established treatment after the failure to standard of care based on steroids and vigabatrin. Converging lines of evidence indicating a role of NR2B subunits of

Externí odkaz: https://doaj.org/article/6e28defa096e430da2342590d5729c98

Zobrazit plný text záznamu

Plný text ve formátu HTML

Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study

Autor: J. Zhang, Jo Collier, J. Zong, Ramanda Wilson, L. Fang, Y.S. Babu, William P. Sheridan, Melanie Cornpropst, Phil Collis

Publikováno v: Allergy. 71:1676-1683

Background Avoralstat is a potent small-molecule oral plasma kallikrein inhibitor under development for treatment of hereditary angioedema (HAE). This first-in-human study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa6f89a0524c1db416155a42f479e40
https://doi.org/10.1111/all.12930

Zobrazit plný text záznamu

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

Autor: Paul A. Dickinson, Kathryn Pickup, Mireille Cantarini, Jo Collier, Paul Frewer, Scott W. Martin, Peter Ballard

Publikováno v: Drug Metabolism and Disposition. 44:1201-1212

Preclinical and clinical studies were conducted to determine the metabolism and pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550. Osimertinib was designed to covalently bind to epidermal growth factor receptors, allowing it to ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de825eb2a4b161017191de280d92237
https://doi.org/10.1124/dmd.115.069203

Zobrazit plný text záznamu

Absolute Bioavailability of Osimertinib in Healthy Adults

Autor: Karen Thomas, Jo Collier, Alex Bramley, Karen So, Karthick Vishwanathan, Stephen English

Publikováno v: Clinical pharmacology in drug development. 8(2)

Osimertinib is a third-generation, central nervous system-active, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) selective for EGFR-TKI sensitizing and T790M resistance mutations. This phase 1, open-label study (NCT02491944) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d741d3479b3ed11a159bf2009385c02c
https://pubmed.ncbi.nlm.nih.gov/29683562

Zobrazit plný text záznamu

PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353, AN ORAL PLASMA KALLIKREIN INHIBITOR, IN HEALTHY JAPANESE SUBJECTS

Autor: Sylvia Dobo, Jo Collier, Phil Collis, Melanie Cornpropst, William P. Sheridan

Publikováno v: Annals of Allergy, Asthma & Immunology. 121:S33

Introduction BCX7353 is an oral kallikrein inhibitor being studied for prevention and treatment of hereditary angioedema (HAE) attacks in Western patients. HAE afflicts all ethnic groups. An ethnobridging study was conducted in healthy Japanese subje

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aafb43dab2ba6a7e224b22d396695c2f
https://doi.org/10.1016/j.anai.2018.09.106

Zobrazit plný text záznamu

LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients

Autor: Arjun Ravi, Tess Schmalbach, Dave Singh, David L. Hava, Fred Reid, Jo Collier, Katie Kane

Publikováno v: 5.2 Monitoring Airway Disease.

Rationale: PUR0200 is a tiotropium bromide formulation engineered in a novel dry powder delivery technology called iSPERSE. iSPERSE offers advantages over traditional technologies in enabling diverse classes of inhaled compounds with improved deliver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a5a5d950b14167426526c214b7556ad
https://doi.org/10.1183/13993003.congress-2015.pa4365

Zobrazit plný text záznamu